Skip to main content
OpenTrials
Completed

NCT Number: NCT01453842

Diet Oil Induced Stimulation of GLP-1

Activation of G protein-coupled receptor GPR119 stimulates glucagon-like peptide-1 (GLP-1)release from the intestinal L-cells. Previously, administration of 2-oleyl-glycerol (2-OG) to humans significantly increased plasma GLP-1. In the present study we want to test the effect in patients with type 2 diabetes. The hypothesis is that we will expect to find a significant increased plasma GLP-1 following a meal containing of 2-OG when compared to meals containing of olive oil or carbohydrates alone.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 2 Diabetes Mellitus Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Department of Clinical Physiology

Glostrup Municipality, 2600, Denmark

About this study

Activation of G protein-coupled receptor GPR119 stimulates glucagon-like peptide-1 (GLP-1)release from the intestinal L-cells. Previously, administration of 2-oleyl-glycerol (2-OG) to humans significantly increased plasma GLP-1. In the present study we want to test the effect in patients with type 2 diabetes. The hypothesis is that we will expect to find a significant increased plasma GLP-1 following a meal containing of 2-OG when compared to meals containing of olive oil or carbohydrates alone. The aim of the study is to elucidate the effect of 2-OG, 'diet oil' on GLP-1 secretion in patients with type 2 diabetes and to explain the mechanism behind the known stimulation of GLP-1 release by dietary fat.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with type 2 diabetes mellitus according to the WHO criteria
  • caucasians
  • age above 18 years
  • BMI 20-30

Exclusion criteria

  • kidney disease
  • liver disease
  • retinopathy
  • anaemia
  • use of insulin
  • use of GLP-1 analogues
  • use of DPP-4 inhibitors

Treatment and study plan

Diet oil

Dietary Supplement

Carrot and diet oil (containing 2-OG) and 1½ g of paracetamol

Olive Oil

Dietary Supplement

Carrot and olive oil and 1½ g of paracetamol

Carrot

Dietary Supplement

Carrot and 1½ g of paracetamol

Primary outcomes

  1. Plasma GLP-1

    Time frame: 3 hours

    Glp-1 response is measured during and three hours after ingestion of the different mealtest

Secondary outcomes

  1. Plasma insulin

    Time frame: 3 hours

    Plasma insulin is measured during and 3 hours after mealtest

  2. Plasma glucose

    Time frame: 3 hours

    Plasma glucose is measured during and 3 hours after meal test

  3. Plasma GIP

    Time frame: 3 hours

    Plasma GIP is measured during and 3 hours after meal test

  4. Plasma glucagon

    Time frame: 3 hours

    Plasma glucagon is measured during and 3 hours after meal test

  5. Plasma PYY

    Time frame: 3 hours

    Plasma PYY is measured during and 3 hours after meal test

  6. Plasma paracetamol

    Time frame: 3 hours

    Plasma paracetamol is measured during and 3 hours after meal test

Sponsors and collaborators

Lead sponsor

University of Copenhagen

Other

Registry information

Important dates

Study start
2011
Primary completion
2011
Study completion
2012
First posted
Oct 18, 2011
Registry last updated
Dec 2, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.